IPD - L-Dex® granted reimbursement status for all cancer related lymphoedema
HIGHLIGHTS
Transformational event for ImpediMed, reimbursement status for use of L-Dex across all relevant cancer types
Expands L-Dex addressable market opportunity to over US$ 350 million per annum
- Forums
- ASX - Short Term Trading
- STT Thread Week Starting 1st Sept.
STT Thread Week Starting 1st Sept., page-59
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)